Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706079 | 1.00 | TLR4 (0.31) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL10005840 | 0.89 | — | — | |
| SCHEMBL1642430 | 0.89 | — | — | |
| SCHEMBL12674234 | 0.89 | — | — | |
| SCHEMBL27104772 | 0.88 | TLR4 (0.30) | TLR4LY96 | |
| SCHEMBL26029373 | 0.88 | LY96 (0.34) | TLR4LY96 | |
| SCHEMBL8059872 | 0.85 | LGALS8 (0.34) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL26029389 | 0.85 | LGALS8 (0.34) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL19389554 | 0.85 | IGF2R (0.34) | TLR4LY96 | |
| SCHEMBL17520392 | 0.85 | IGF2R (0.34) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | TLR4 3203/4885LY96 3615/4885CYP2C19 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.